RGEN (Repligen Corp)
Insider Trading Activity
Every open-market purchase and sale reported by RGEN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Violetta Hughes | CHIEF ACCOUNTING OFFICER | MIXED | — | — |
| 2026-08-21 | Olivier Loeillot | Chief Executive Officer | MIXED | — | — |
| 2026-07-17 | Jason K Garland | CFO | Sell | — | — |
| 2026-06-26 | Jason K Garland | CFO | Sell | — | — |
| 2026-05-18 | NICOLAS BARTHELEMY | Director | A | — | — |
| 2026-05-18 | KAREN A DAWES | Director | A | — | — |
| 2026-05-18 | GLENN P MUIR | Director | A | — | — |
| 2026-05-18 | Margaret Pax | Director | A | — | — |
| 2026-05-18 | Rohin Mhatre | Director | A | — | — |
| 2026-05-18 | MANNER CARRIE EGLINTON | Director | A | — | — |
| 2026-05-18 | Konstantin Konstantinov | Director | A | — | — |
| 2026-05-18 | Martin D Madaus | Director | A | — | — |
| 2026-05-08 | Brian Robb Douglass | CHIEF PRODUCT OFFICER | F | — | — |
| 2026-05-08 | GLENN P MUIR | Director | M | — | — |
| 2026-04-22 | Olivier Loeillot | Chief Executive Officer | Sell | — | — |
| 2026-03-23 | Jason K Garland | CFO | A | — | — |
| 2026-03-23 | James Bylund | Chief Operating Officer | A | — | — |
| 2026-03-23 | Olivier Loeillot | Chief Executive Officer | A | — | — |
| 2026-03-23 | RALF KURIYEL | Senior VP, R&D | A | — | — |
| 2026-03-05 | RALF KURIYEL | Senior VP, R&D | MIXED | — | — |
| 2026-03-05 | James Bylund | Chief Operating Officer | MIXED | — | — |
| 2026-03-03 | Brian Robb Douglass | CHIEF PRODUCT OFFICER | F | — | — |
| 2026-03-03 | RALF KURIYEL | Senior VP, R&D | F | — | — |
| 2026-03-03 | Jason K Garland | CFO | F | — | — |
| 2026-03-03 | Anthony Hunt | Director | F | — | — |
| 2026-03-03 | Olivier Loeillot | Chief Executive Officer | F | — | — |
| 2026-03-03 | James Bylund | Chief Operating Officer | F | — | — |
| 2026-01-12 | Brian Robb Douglass | CHIEF PRODUCT OFFICER | A | — | — |
| 2025-12-18 | KAREN A DAWES | Director | Sell | — | — |
| 2025-12-17 | GLENN P MUIR | Director | M | — | — |
| 2025-12-08 | Anthony Hunt | Director | J | — | — |
| 2025-11-26 | Olivier Loeillot | Chief Executive Officer | Sell | — | — |
| 2025-11-19 | James Bylund | Chief Operating Officer | Sell | — | — |
| 2025-11-14 | Anthony Hunt | Director | MIXED | — | — |
| 2025-11-13 | Anthony Hunt | Director | MIXED | — | — |
| 2025-10-06 | Olivier Loeillot | Chief Executive Officer | F | — | — |
| 2025-09-26 | Jason K Garland | CFO | F | — | — |
| 2025-09-11 | Anthony Hunt | Director | MIXED | — | — |
| 2025-09-04 | Olivier Loeillot | Chief Executive Officer | F | — | — |
| 2025-09-04 | Violetta Hughes | CHIEF ACCOUNTING OFFICER | A | — | — |
| 2025-08-12 | Martin D Madaus | Director | Buy | — | — |
| 2025-05-21 | NICOLAS BARTHELEMY | Director | A | — | — |
| 2025-05-19 | Rohin Mhatre | Director | A | — | — |
| 2025-05-19 | Margaret Pax | Director | A | — | — |
| 2025-05-19 | Martin D Madaus | Director | A | — | — |
| 2025-05-19 | KAREN A DAWES | Director | A | — | — |
| 2025-05-19 | MANNER CARRIE EGLINTON | Director | A | — | — |
| 2025-05-19 | GLENN P MUIR | Director | A | — | — |
| 2025-05-19 | Konstantin Konstantinov | Director | A | — | — |
| 2025-05-16 | Anthony Hunt | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,795,100 | — |
| — | 10%+ Owner | 727,518 | — |
| — | Director | 665,106 | — |
| — | Director | 441,500 | — |
| — | PRESIDENT, CEO | 262,430 | — |
| — | Senior Vice President | 127,516 | — |
| — | Senior Vice President | 94,708 | — |
| — | Director | 92,816 | — |
| — | Director | 89,062 | — |
| — | Director | 59,709 | — |
| — | Chief Executive Officer | 59,672 | — |
| — | VP Business Development | 46,637 | — |
| — | Director | 40,331 | — |
| — | Director | 40,051 | — |
| — | Chief Financial Officer | 37,381 | — |
| — | See Remarks | 27,419 | — |
| — | Chief Operating Officer | 25,423 | — |
| — | Director | 21,380 | — |
| — | Senior VP, R&D | 20,062 | — |
| — | CFO | 18,829 | — |
| — | CFO | 15,000 | — |
| — | Director | 8,381 | — |
| — | CHIEF PRODUCT OFFICER | 7,985 | — |
| — | CHIEF ACCOUNTING OFFICER | 6,608 | — |
| — | Director | 5,461 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RGEN quote page; the site-wide leaderboard is on the insider transactions hub.